Log In
Print
BCIQ
Print
Print this Print this
 

PRO 140

  Manage Alerts
Collapse Summary General Information
Company CytoDyn Inc.
DescriptionHumanized mAb against CC chemokine receptor 5 (CCR5; CD195)
Molecular Target CC chemokine receptor 5 (CCR5) (CD195)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection
Regulatory Designation

U.S. - Fast Track (Treat HIV infection)

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$10.0M

$3.5M

$6.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today